Search

Your search keyword '"Dinner, Shira"' showing total 324 results
Start Over Author "Dinner, Shira"
324 results on '"Dinner, Shira"'

1. Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence.

Author

Xie, Zhuoer, Komrokji, Rami S, Al-Ali, Najla, Regelson, Alexandra, Geyer, Susan, Patel, Anand A, Saygin, Caner, Zeidan, Amer M, Bewersdorf, Jan Philipp, Mendez, Lourdes M, Kishtagari, Ashwin, Zeidner, Joshua F, Coombs, Catherine C, Madanat, Yazan F, Chung, Stephen S, Badar, Talha, Foran, James M, Desai, Pinkal, Tsai, Charlton, Griffiths, Elizabeth A, Al Malki, Monzr M, Amanam, Idoroenyi, Lai, Catherine, Deeg, H Joachim, Ades, Lionel, Arana-Yi, Cecilia, Osman, Afaf Eg, Dinner, Shira Naomi, Abaza, Yasmin, Taylor, Justin, Chandhok, Namrata S, Soong, Deborah, Brunner, Andrew M, Carraway, Hetty E, Singh, Abhay, Elena, Chiara, Ferrari, Jacqueline, Galli, Anna, Pozzi, Sara, Padron, Eric, Patnaik, Mrinal M, Malcovati, Luca, Savona, Michael R, and Al-Kali, Aref

Subjects
Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology, Biochemistry and cell biology, Cardiovascular medicine and haematology, Paediatrics
Abstract

Clonal cytopenia of undetermined significance (CCUS) represents a distinct disease entity characterized by myeloid-related somatic mutations with a variant allele fraction of ≥2% in individuals with unexplained cytopenia(s) but without a myeloid neoplasm (MN). Notably, CCUS carries a risk of progressing to MN, particularly in cases featuring high-risk mutations. Understanding CCUS requires dedicated studies to elucidate its risk factors and natural history. Our analysis of 357 CCUS patients investigated the interplay between clonality, cytopenia, and prognosis. Multivariate analysis identified 3 key adverse prognostic factors: the presence of splicing mutation(s) (score = 2 points), platelet count

Published
2024

2. A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies

Author

Davids, Matthew S., Brander, Danielle M., Alvarado-Valero, Yesid, Diefenbach, Catherine S., Egan, Daniel N., Dinner, Shira N., Javidi-Sharifi, Nathalie, Al Malki, Monzr M., Begna, Kebede H., Bhatt, Vijaya Raj, Abedin, Sameem, Cook, Rachel J., Collins, Mary C., Roleder, Carly, Dominguez, Edward C., Rajagopalan, Prabhu, Wiley, Sandra E., Ghalie, Richard G., and Danilov, Alexey V.

Published
2025
Full Text
View/download PDF

4. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

Author

Woyach, Jennifer A., Perez Burbano, Gabriela, Ruppert, Amy S., Miller, Cecelia, Heerema, Nyla A., Zhao, Weiqiang, Wall, Anna, Ding, Wei, Bartlett, Nancy L., Brander, Danielle M., Barr, Paul M., Rogers, Kerry A., Parikh, Sameer A., Stephens, Deborah M., Brown, Jennifer R., Lozanski, Gerard, Blachly, James, Nattam, Sreenivasa, Larson, Richard A., Erba, Harry, Litzow, Mark, Luger, Selina, Owen, Carolyn, Kuzma, Charles, Abramson, Jeremy S., Little, Richard F., Dinner, Shira, Stone, Richard M., Uy, Geoffrey, Stock, Wendy, Mandrekar, Sumithra J., and Byrd, John C.

Published
2024
Full Text
View/download PDF

5. Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author

Badar, Talha, Atallah, Ehab, Shallis, Rory, Saliba, Antoine N., Patel, Anand, Bewersdorf, Jan P., Grenet, Justin, Stahl, Maximilian, Duvall, Adam, Burkart, Madelyn, Palmisiano, Neil, Bradshaw, Danielle, Kubiak, Michal, Dinner, Shira, Goldberg, Aaron D., Abaza, Yasmin, Murthy, Guru Subramanian Guru, Kota, Vamsi, and Litzow, Mark R.

Published
2023
Full Text
View/download PDF

6. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

Author

Voorhees, Peter M, Sborov, Douglas W, Laubach, Jacob, Kaufman, Jonathan L, Reeves, Brandi, Rodriguez, Cesar, Chari, Ajai, Silbermann, Rebecca, Costa, Luciano J, Anderson, Larry D, Jr, Nathwani, Nitya, Shah, Nina, Bumma, Naresh, Efebera, Yvonne A, Holstein, Sarah A, Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M, Orlowski, Robert Z, Shain, Kenneth H, Cowan, Andrew J, Dinner, Shira, Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas S, Usmani, Saad Z, and Richardson, Paul G

Published
2023
Full Text
View/download PDF

7. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Author

Watts, Justin M, Baer, Maria R, Yang, Jay, Prebet, Thomas, Lee, Sangmin, Schiller, Gary J, Dinner, Shira N, Pigneux, Arnaud, Montesinos, Pau, Wang, Eunice S, Seiter, Karen P, Wei, Andrew H, De Botton, Stephane, Arnan, Montserrat, Donnellan, Will, Schwarer, Anthony P, Récher, Christian, Jonas, Brian A, Ferrell, P Brent, Jr, Marzac, Christophe, Kelly, Patrick, Sweeney, Jennifer, Forsyth, Sanjeev, Guichard, Sylvie M, Brevard, Julie, Henrick, Patrick, Mohamed, Hesham, and Cortes, Jorge E

Published
2023
Full Text
View/download PDF

8. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Author

Kreitman, Robert, Dearden, Claire, Zinzani, Pier, Delgado, Julio, Karlin, Lionel, Robak, Tadeusz, Gladstone, Douglas, le Coutre, Philipp, Dietrich, Sascha, Gotic, Mirjana, Larratt, Loree, Offner, Fritz, Schiller, Gary, Swords, Ronan, Bacon, Larry, Bocchia, Monica, Bouabdallah, Krimo, Breems, Dimitri, Cortelezzi, Agostino, Dinner, Shira, Doubek, Michael, Gjertsen, Bjorn, Gobbi, Marco, Hellmann, Andrzej, Lepretre, Stephane, Maloisel, Frederic, Ravandi, Farhad, Rousselot, Philippe, Rummel, Mathias, Siddiqi, Tanya, Tadmor, Tamar, Troussard, Xavier, Yi, Cecilia, Saglio, Giuseppe, Roboz, Gail, Balic, Kemal, Standifer, Nathan, He, Peng, Marshall, Shannon, Wilson, Wyndham, Pastan, Ira, Yao, Nai-Shun, and Giles, Francis

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Bacterial Toxins, Drug Resistance, Neoplasm, Exotoxins, Female, Follow-Up Studies, Humans, Leukemia, Hairy Cell, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Remission Induction, Salvage Therapy, Survival Rate
Abstract

This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL who had ≥2 prior systemic therapies, including ≥1 purine nucleoside analog. Patients received moxetumomab pasudotox 40 µg/kg intravenously on days 1, 3, and 5 every 28 days for ≤6 cycles. Blinded independent central review determined disease response and minimal residual disease (MRD) status. Among 80 patients (79% males; median age, 60.0 years), durable complete response (CR) rate was 30%, CR rate was 41%, and objective response rate (CR and partial response) was 75%; 64 patients (80%) achieved hematologic remission. Among complete responders, 27 (85%) achieved MRD negativity by immunohistochemistry. The most frequent adverse events (AEs) were peripheral edema (39%), nausea (35%), fatigue (34%), and headache (33%). Treatment-related serious AEs of hemolytic uremic syndrome (7.5%) and capillary leak syndrome (5%) were reversible and generally manageable with supportive care and treatment discontinuation (6 patients; 7.5%). Moxetumomab pasudotox treatment achieved a high rate of independently assessed durable response and MRD eradication in heavily pretreated patients with HCL, with acceptable tolerability.

Published
2018

9. Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data

Author

Badar, Talha, Szabo, Aniko, Litzow, Mark, Burkart, Madelyn, Yurkiewicz, Ilana, Dinner, Shira, Hefazi, Mehrdad, Shallis, Rory M., Podoltsev, Nikolai, Patel, Anand A., Curran, Emily, Wadleigh, Martha, Balasubramanian, Suresh, Yang, Jay, Arslan, Shukaib, Aldoss, Ibrahim, Mattison, Ryan, Cenin, Danielle, Siebenaller, Caitlin, Advani, Anjali, Liedtke, Michaela, and Atallah, Ehab

Published
2021
Full Text
View/download PDF

11. A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol.

Author

Palmisiano, Neil D., Lee, Ju‐Whei, Claxton, David F., Paietta, Elisabeth M., Alkhateeb, Hassan, Park, Jae, Podoltsev, Nikolai A., Atallah, Ehab L., Schaar, Dale G., Dinner, Shira N., Webster, Jonathan A., Luger, Selina M., and Litzow, Mark R.

Published
2024
Full Text
View/download PDF

12. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin

Author

Badar, Talha, Szabo, Aniko, Wadleigh, Martha, Liedtke, Michaela, Arslan, Shukaib, Siebenaller, Caitlin, Aldoss, Ibrahim, Schultz, Elizabeth, Hefazi, Mehrdad, Litzow, Mark R., Kuo, Eric, Wang, Amy, Curran, Emily, Shallis, Rory M., Podoltsev, Nikolai, Balasubramanian, Suresh, Yang, Jay, Mattison, Ryan, Burkart, Madelyn, Dinner, Shira, Advani, Anjali, and Atallah, Ehab

Published
2020
Full Text
View/download PDF

13. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab

Author

Badar, Talha, Szabo, Aniko, Advani, Anjali, Wadleigh, Martha, Arslan, Shukaib, Khan, Muhammad Ali, Aldoss, Ibrahim, Siebenaller, Caitlin, Schultz, Elizabeth, Hefazi, Mehrdad, Shallis, Rory M., Yurkiewicz, Ilana, Podoltsev, Nikolai, Patel, Anand A., Curran, Emily, Balasubramanian, Suresh, Yang, Jay, Mattison, Ryan J., Burkart, Madelyn, Dinner, Shira, Liedtke, Michaela, Litzow, Mark R., and Atallah, Ehab

Published
2020
Full Text
View/download PDF

16. Dosing of 7 + 3 induction chemotherapy in a patient with acute myeloid leukemia (AML) and morbid obesity.

Author

Franco, Stephanie, Khan, Talha, Dinner, Shira, Karmali, Reem, and Melody, Megan

Subjects
BODY surface area, BODY mass index, PATIENT safety, ANTINEOPLASTIC agents, DISEASE remission, TREATMENT effectiveness, CYTARABINE, REMISSION induction, ANTHRACYCLINES, MORBID obesity, INDUCTION chemotherapy, DAUNOMYCIN
Abstract

Introduction: Traditional chemotherapy dosing is based on body surface area (BSA) using standard formulas, which can pose challenges in dosing patients at body weight extremes. Studies suggest that chemotherapy dosing according to actual body weight does not increase toxicity in obese patients and current guidelines recommend full weight-based dosing of chemotherapy regardless of body mass index (BMI). However, the dosing of anthracyclines in obese patients can be challenging given limitations in maximum cumulative dosage, particularly in those at very extreme BMI. In this case, we highlight the difficulties of dosing anthracycline-based induction chemotherapy in a patient with newly diagnosed acute myeloid leukemia (AML) and BMI >90 kg/m2. Case report: A 40-year-old female with morbid obesity is diagnosed with AML (nucleophosmin 1 (NPMI) and isocitrate dehydrogenase-2 mutated, FMS-like tyrosine kinase 3-Internal tandem duplication negative). Management and Outcome: The patient was initiated on induction therapy with 7 + 3 with dose capping of BSA at 2.75 m2 (cytarabine 200 mg/m2 continuous infusion over 24 h for 7 days, plus daunorubicin 60 mg/m2 slow intravenous push for 3 days), followed by two cycles of high-dose cytarabine consolidation therapy using actual BSA. The patient achieved morphologic complete remission; however, measurable residual disease testing for NPM1 remained positive after induction therapy. Discussion: This case suggests that dose capping of anthracyclines in the treatment of newly diagnosed AML may be an effective and safe treatment alternative in those with extreme BMI elevations beyond what has been studied in the literature. Given the increasing incidence of morbid obesity, further studies are needed to confirm appropriate dosing of anthracycline-based regimens at upper BMI extremes (>60 kg/m2). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia

Author

Efficace, Fabio, primary, Cottone, Francesco, additional, Yanez, Betina, additional, Kota, Vamsi, additional, Castagnetti, Fausto, additional, Caocci, Giovanni, additional, Bonifacio, Massimiliano, additional, Patriarca, Andrea, additional, Capodanno, Isabella, additional, Miggiano, Maria Cristina, additional, Tiribelli, Mario, additional, Breccia, Massimo, additional, Luciano, Luigia, additional, Giai, Valentina, additional, Iurlo, Alessandra, additional, Abruzzese, Elisabetta, additional, Fava, Carmen, additional, Dinner, Shira, additional, Altman, Jessica K., additional, Rosti, Gianantonio, additional, Cortes, Jorge, additional, Vignetti, Marco, additional, and Cella, David, additional

Published
2023
Full Text
View/download PDF

20. Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Author

Bhatia, Smita, primary, Pappo, Alberto S., additional, Acquazzino, Melissa, additional, Allen-Rhoades, Wendy A., additional, Barnett, Marie, additional, Borinstein, Scott C., additional, Casey, Robert, additional, Choo, Sun, additional, Chugh, Rashmi, additional, Dinner, Shira, additional, Ermoian, Ralph, additional, Fair, Douglas, additional, Federman, Noah, additional, Folbrecht, Jeanelle, additional, Gandhi, Shipra, additional, Germann, Julie, additional, Goldsby, Robert, additional, Hayashi, Robert, additional, Huang, Alex Y., additional, Huang, Mary S., additional, Jacobs, Linda A., additional, Lee-Miller, Cathy, additional, Link, Michael P., additional, Livingston, John A., additional, Lustberg, Maryam, additional, Malogolowkin, Marcio, additional, Oeffinger, Kevin C., additional, Pratilas, Christine A., additional, Reed, Damon, additional, Skiles, Jodi, additional, von Mehren, Margaret, additional, Yeager, Nicholas, additional, Montgomery, Sarah, additional, and Hang, Lisa, additional

Published
2023
Full Text
View/download PDF

21. S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910

Author

Litzow, Mark, primary, Sun, Zhuoxin, additional, Mattison, Ryan, additional, Paietta, Elisabeth, additional, Mullighan, Charles, additional, Roberts, Kathryn, additional, Zhang, Yanming, additional, Racevskis, Janis, additional, Willman, Cheryl, additional, Wieduwilt, Matthew, additional, Liedtke, Michaela, additional, Bergeron, Julie, additional, Lazarus, Hillard, additional, Arber, Dan, additional, Wood, Brent, additional, Rowe, Jacob, additional, Pratz, Keith, additional, Dinner, Shira, additional, Frey, Noelle, additional, Gore, Steve, additional, Bhatnagar, Bhavana, additional, Atallah, Ehab, additional, Uy, Geoff, additional, Jeyakumar, Deepa, additional, Lin, Tara, additional, Patel, Shejal, additional, Elliott, Michelle, additional, Advani, Anjali, additional, Deangelo, Daniel, additional, Tzachanis, Dimitrios, additional, Vachhani, Pankit, additional, Bhave, Rupali, additional, Little, Richard, additional, Erba, Harry, additional, Stone, Richard, additional, Luger, Selina, additional, and Tallman, Martin, additional

Published
2023
Full Text
View/download PDF

22. S117: CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703

Author

Wieduwilt, Matthew, primary, Yin, Jun, additional, Kour, Oudom, additional, Teske, Rebecca, additional, Stock, Wendy, additional, Byrd, Ken, additional, Doucette, Kimberly, additional, Mangan, James, additional, Masters, Gregory, additional, Mims, Alice, additional, Jamieson, Katarzyna, additional, Dinner, Shira, additional, Bseiso, Ali, additional, Uy, Geoffrey, additional, Erba, Harry, additional, Litzow, Mark, additional, and Stone, Richard, additional

Published
2023
Full Text
View/download PDF

23. Patient‐reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.

Author

Efficace, Fabio, Cottone, Francesco, Yanez, Betina, Kota, Vamsi, Castagnetti, Fausto, Caocci, Giovanni, Bonifacio, Massimiliano, Patriarca, Andrea, Capodanno, Isabella, Miggiano, Maria Cristina, Tiribelli, Mario, Breccia, Massimo, Luciano, Luigia, Giai, Valentina, Iurlo, Alessandra, Abruzzese, Elisabetta, Fava, Carmen, Dinner, Shira, Altman, Jessica K., and Rosti, Gianantonio

Subjects
CHRONIC myeloid leukemia, PATIENT compliance, CHRONIC leukemia, PROTEIN-tyrosine kinase inhibitors, SYMPTOMS, TABLET computers
Abstract

Background: The authors assessed the clinical utility of patient‐reported symptom monitoring in the setting of newly diagnosed chronic myeloid leukemia (CML). The primary objective was to evaluate adherence to therapy. Methods: The authors conducted an international prospective study that included patients with newly diagnosed, chronic‐phase CML. Before clinical consultation, patients were provided a tablet computer to self‐rate their symptoms, and the results were available in real time to each physician during the patient's visit. Adherence was assessed by pill count and with a validated self‐reported questionnaire. The proportions of optimal responders at 3 and 6 months were assessed according to the European LeukemiaNet criteria. Results: Between July 2020 and August 2021, 94 patients with a median age of 57 years were enrolled. Pill count adherence analysis indicated that 86 of 93 evaluable patients (92.5%) took at least 90% of prescribed tyrosine kinase inhibitor therapy during the 6‐month observation period. The online platform was well accepted by patients and physicians. An optimal response was achieved by 69 of 79 patients (87.3%) at 3 months and by 61 of 81 patients (75.3%) at 6 months. Conclusions: Patient‐reported symptom monitoring from the beginning of therapy in patients with CML may be critical to improve adherence to therapy and early molecular response rates (ClinicalTrials.gov identifier NCT04384848). Optimal adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia is critical to attain and maintain an optimal clinical response. The current findings suggest that systematic monitoring of patient‐reported symptoms is associated with high adherence rates. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Allogeneic stem cell transplant improves survival after first- or second-line therapy in TP53-mutated acute myeloid leukemia: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).

Author

Badar, Talha, primary, Atallah, Ehab, additional, Shallis, Rory, additional, Saliba, Antoine, additional, Patel, Anand, additional, Bewersdorf, Jan, additional, Grenet, Justin, additional, Stahl, Maximilian, additional, Duvall, Adam, additional, Burkart, Madelyn, additional, Palmisiano, Neil, additional, Bradshaw, Danielle, additional, Kubiak, Michal, additional, Dinner, Shira, additional, Goldberg, Aaron, additional, Abaza, Yasmin, additional, Murthy, Guru Subramanian Guru, additional, Kota, Vamsi, additional, and Litzow, Mark, additional

Published
2022
Full Text
View/download PDF

25. Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia

Author

Badar, Talha, primary, Litzow, Mark R., additional, Shallis, Rory M., additional, Patel, Anand, additional, Saliba, Antoine N., additional, Burkart, Madelyn, additional, Bewersdorf, Jan P., additional, Stahl, Maximilian, additional, De Camargo Correia, Guilherme Sacchi, additional, Guru Murthy, Guru Subramanian, additional, Abaza, Yasmin, additional, Duvall, Adam, additional, Bradshaw, Danielle, additional, Kota, Vamsi, additional, Dinner, Shira, additional, Goldberg, Aaron D., additional, Palmisiano, Neil, additional, Al Kali, Aref, additional, and Atallah, Ehab, additional

Published
2022
Full Text
View/download PDF

27. Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Author

Litzow, Mark R., primary, Sun, Zhuoxin, additional, Paietta, Elisabeth, additional, Mattison, Ryan J., additional, Lazarus, Hillard M, additional, Rowe, Jacob M., additional, Arber, Daniel A., additional, Mullighan, Charles G., additional, Willman, Cheryl L, additional, Zhang, Yanming, additional, Wieduwilt, Matthew, additional, Liedtke, Michaela, additional, Bergeron, Julie, additional, Pratz, Keith W., additional, Dinner, Shira, additional, Frey, Noelle V., additional, Gore, Steven D., additional, Bhatnagar, Bhavana, additional, Atallah, Ehab L., additional, Uy, Geoffrey L., additional, Jeyakumar, Deepa, additional, Lin, Tara L., additional, Little, Richard F., additional, Luger, Selina M., additional, and Tallman, Martin S., additional

Published
2022
Full Text
View/download PDF

29. Contributors

Author

Abdel-Wahab, Omar, primary, Abrahm, Janet L., additional, Adams, Sharon, additional, Adewoye, Adeboye H., additional, Allen, Carl, additional, Ambinder, Richard F., additional, Anasetti, Claudio, additional, Anastasi, John, additional, Anderson, Julia A., additional, Antin, Joseph H., additional, Antony, Aśok C., additional, Araten, David J., additional, Armand, Philippe, additional, Armstrong, Gillian, additional, Armstrong, Scott A., additional, Arnold, Donald M., additional, Artz, Andrew S., additional, Awan, Farrukh T., additional, Baglin, Trevor P., additional, Benson, Don M., additional, Benz, Edward J., additional, Berliner, Nancy, additional, Bhagat, Govind, additional, Bhardwaj, Nina, additional, Bhatia, Ravi, additional, Bhatia, Smita, additional, Bhatt, Mihir D., additional, Bhatt, Vijaya Raj, additional, Bitan, Menachem, additional, Blinderman, Craig D., additional, Bollard, Catherine M., additional, Braun, Benjamin S., additional, Brenner, Malcolm K., additional, Brittenham, Gary M., additional, Brodsky, Robert A., additional, Brown, Myles, additional, Broxmeyer, Hal E., additional, Brummel-Ziedins, Kathleen, additional, Brunner, Andrew M., additional, Buadi, Francis K., additional, Burkhardt, Birgit, additional, Burns, Melissa, additional, Byrd, John C., additional, Caimi, Paolo F., additional, Caligiuri, Michael A., additional, Canavan, Michelle, additional, Cantor, Alan B., additional, Carcao, Manuel, additional, Carroll, Michael C., additional, Carty, Shannon A., additional, Castillo, Jorge J., additional, Chan, Anthony K.C., additional, Chapin, John, additional, Chiu, April, additional, Chute, John P., additional, Clark, David B., additional, Coates, Thomas D., additional, Cogle, Christopher R., additional, Connell, Nathan T., additional, Cooke, Elizabeth, additional, Cooley, Sarah, additional, Corradini, Paolo, additional, Creager, Mark A., additional, Creger, Richard J., additional, Cromwell, Caroline, additional, Crowther, Mark A., additional, Cushing, Melissa M., additional, Cutler, Corey, additional, Dang, Chi V., additional, Danial, Nika N., additional, Dave, Sandeep S., additional, DeCaprio, James A., additional, Dinauer, Mary C., additional, Dinner, Shira, additional, Diz-Küçükkaya, Reyhan, additional, Dodd, Roger Y., additional, Donato, Michele L., additional, Dorshkind, Kenneth, additional, Dotti, Gianpietro, additional, Dror, Yigal, additional, Dunleavy, Kieron, additional, Dvorak, Christopher C., additional, Ebert, Benjamin L., additional, Eck, Michael J., additional, Eikelboom, John W., additional, Epperla, Narendranath, additional, Ershler, William B., additional, Evans, William E., additional, Faderl, Stefan, additional, Ferrara, James L.M., additional, Filipovich, Alexandra Hult, additional, Fischer, Martin, additional, Fredenburgh, James C., additional, Friedman, Kenneth D., additional, Fuchs, Ephraim, additional, Fuller, Stephen J., additional, Gailani, David, additional, Galipeau, Jacques, additional, Gallagher, Patrick G., additional, Ganapathi, Karthik A., additional, Gardner, Lawrence B., additional, Gee, Adrian P., additional, Gerson, Stanton L., additional, Gertz, Morie A., additional, Giardina, Patricia J., additional, Gibson, Christopher J., additional, Golan, Karin, additional, Golub, Todd R., additional, Gonzales, Matthew J., additional, Gotlib, Jason, additional, Gottschalk, Stephen, additional, Grant, Marianne A., additional, Graubert, Timothy A., additional, Gregg, Xylina T., additional, Gribben, John G., additional, Gross, Dawn M., additional, Gruber, Tanja A., additional, Guitart, Joan, additional, Gurbuxani, Sandeep, additional, Gur-Cohen, Shiri, additional, Gutierrez, Alejandro, additional, Hamadani, Mehdi, additional, Hari, Parameswaran N., additional, Hartwig, John H., additional, Hayman, Suzanne R., additional, Hayward, Catherine P.M., additional, Hebbel, Robert P., additional, Heslop, Helen E., additional, Hillis, Christopher, additional, Hillyer, Christopher D., additional, Ho, Karin, additional, Hockenbery, David M., additional, Hoffman, Ronald, additional, Hogg, Kerstin E., additional, Holtan, Shernan G., additional, Horny, Hans-Peter, additional, Hsu, Yen-Michael S., additional, Hunter, Zachary R., additional, Huntington, James A., additional, Iancu-Rubin, Camelia, additional, Iqbal, Ali, additional, Isenman, David E., additional, Israels, Sara J., additional, Italiano, Joseph E., additional, Jaffe, Elaine S., additional, Jaffer, Iqbal H., additional, Jagannath, Sundar, additional, Jäger, Ulrich, additional, Jain, Nitin, additional, James, Paula, additional, Jeha, Sima, additional, Jordan, Michael B., additional, Josephson, Cassandra D., additional, Jung, Moonjung, additional, Kager, Leo, additional, Kambayashi, Taku, additional, Kanakry, Jennifer A., additional, Kantarjian, Hagop M., additional, Kaplan, Jason, additional, Karafin, Matthew S., additional, Karsan, Aly, additional, Kaufman, Randal J., additional, Kaufman, Richard M., additional, Keller, Frank G., additional, Kelly, Kara M., additional, Kessler, Craig M., additional, Key, Nigel S., additional, Keyzner, Alla, additional, Khandoga, Alexander G., additional, Khanna-Gupta, Arati, additional, Khatib-Massalha, Eman, additional, Klein, Harvey G., additional, Knoechel, Birgit, additional, Kollet, Orit, additional, Konkle, Barbara A., additional, Kontoyiannis, Dimitrios P., additional, Koreth, John, additional, Koretzky, Gary A., additional, Kotecha, Dipak, additional, Kremyanskaya, Marina, additional, Kumari, Anju, additional, Kuzel, Timothy M., additional, Küppers, Ralf, additional, Lacy, Martha Q., additional, Ladas, Elana, additional, Landier, Wendy, additional, Lapid, Kfir, additional, Lapidot, Tsvee, additional, Larson, Peter J., additional, Levi, Marcel, additional, Lewis, Russell E., additional, Liebman, Howard A., additional, Lillicrap, David, additional, Lim, Wendy, additional, Lin, Judith C., additional, Lindblad, Robert, additional, Lip, Gregory Y.H., additional, Little, Jane A., additional, Lohr, Jens G., additional, López, José A., additional, Luscinskas, Francis W., additional, Maciejewski, Jaroslaw P., additional, Majhail, Navneet S., additional, Manches, Olivier, additional, Mandle, Robert J., additional, Mann, Kenneth G., additional, Manno, Catherine S., additional, Marcogliese, Andrea N., additional, Mariani, Guglielmo, additional, Marincola, Francesco M., additional, Mascarenhas, John, additional, Massberg, Steffen, additional, McEver, Rodger P., additional, McGrath, Emer, additional, McKinney, Matthew S., additional, Mehta, Rohtesh S., additional, Mentzer, William C., additional, Merlini, Giampaolo, additional, Merryman, Reid, additional, Michel, Marc, additional, Migliaccio, Anna Rita, additional, Miller, Jeffrey S., additional, Mims, Martha P., additional, Mondoro, Traci Heath, additional, Moorehead, Paul, additional, Muniz, Luciana R., additional, Munshi, Nikhil C., additional, Najfeld, Vesna, additional, Nayak, Lalitha, additional, Nazy, Ishac, additional, Neff, Anne T., additional, Ness, Paul M., additional, Notarangelo, Luigi D., additional, O'Brien, Sarah H., additional, O'Connor, Owen A., additional, O'Donnell, Martin, additional, Olson, Amanda, additional, Orkin, Stuart H., additional, Pai, Menaka, additional, Pai, Sung-Yun, additional, Paidas, Michael, additional, Panch, Sandhya R., additional, Pande, Reena L., additional, Papayannopoulou, Thalia, additional, Parikh, Rahul, additional, Petersdorf, Effie W., additional, Peterson, Shane E., additional, Pittaluga, Stefania, additional, Ponce, Doris M., additional, Popolo, Laura, additional, Prchal, Josef T., additional, Pui, Ching-Hon, additional, Puigserver, Pere, additional, Rak, Janusz, additional, Ramos, Carlos A., additional, Rand, Jacob H., additional, Rand, Margaret L., additional, Rao, Dinesh S., additional, Ravandi, Farhad, additional, Rawlings, David J., additional, Reddy, Pavan, additional, Reding, Mark T., additional, Reiter, Andreas, additional, Rice, Lawrence, additional, Riese, Matthew J., additional, Ritchey, Arthur Kim, additional, Roberts, David J., additional, Roman, Elizabeth, additional, Rooney, Cliona M., additional, Rosen, Steven T., additional, Rosenthal, David S., additional, Rossmann, Marlies P., additional, Rot, Antal, additional, Rowley, Scott D., additional, Rubnitz, Jeffrey E., additional, Rydz, Natalia, additional, Salama, Mohamed E., additional, Sauk, Steven, additional, Saunthararajah, Yogen, additional, Savage, William, additional, Scadden, David, additional, Schaefer, Kristen G., additional, Schiffman, Fred, additional, Schneidewend, Robert, additional, Schrier, Stanley L., additional, Schuchman, Edward H., additional, Scullion, Bridget Fowler, additional, Selvaggi, Kathy J., additional, Senoo, Keitaro, additional, Shaheen, Montaser, additional, Shaz, Beth H., additional, Shelburne, Samuel A., additional, Shpall, Elizabeth J., additional, Shurin, Susan B., additional, Siegal, Deborah, additional, Silberstein, Leslie E., additional, Silberstein, Lev, additional, Silverstein, Roy L., additional, Sloan, Steven R., additional, Smith, Franklin O., additional, Smith, James W., additional, Smith, Katy, additional, Steensma, David P., additional, Steinberg, Martin H., additional, Stock, Wendy, additional, Storry, Jill R., additional, Stramer, Susan L., additional, Strauss, Ronald G., additional, Stroncek, David F., additional, Taylor, Justin, additional, Thota, Swapna, additional, Treon, Steven P., additional, Tulpule, Anil, additional, Valdes, Roberto Ferro, additional, Valent, Peter, additional, Vedantham, Suresh, additional, Vercellotti, Gregory M., additional, Verneris, Michael R., additional, Vichinsky, Elliott P., additional, von Andrian, Ulrich H., additional, Vose, Julie M., additional, Wagner, Andrew J., additional, Wang, Ena, additional, Wang, Jia-huai, additional, Warkentin, Theodore E., additional, Wasserstein, Melissa P., additional, Webster, Ann, additional, Weisdorf, Daniel J., additional, Weitz, Jeffrey I., additional, Westhoff, Connie M., additional, Wheeler, Allison P., additional, Widick, Page, additional, Wiley, James S., additional, William, Basem M., additional, Williams, David A., additional, Wilson, Wyndham H., additional, Wolfe, Joanne, additional, Wolgast, Lucia R., additional, Wood, Deborah, additional, Wu, Jennifer, additional, Yahalom, Joachim, additional, Yee, Donald L., additional, Younes, Anas, additional, Young, Neal S., additional, and Zeller, Michelle P., additional

Published
2018
Full Text
View/download PDF

31. Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author

Badar, Talha, primary, Atallah, Ehab L., additional, Shallis, Rory Michael, additional, Saliba, Antoine N., additional, Stahl, Maximilian F., additional, Bewersdorf, Jan Philipp, additional, Grenet, Justin, additional, Patel, Anand Ashwin, additional, Abaza, Yasmin, additional, Guru Murthy, Guru Subramanian, additional, Duvall, Adam S, additional, Burkart, Madelyn, additional, Palmisiano, Neil, additional, Kubiak, Michal Jakub, additional, Kota, Vamsi K., additional, Dinner, Shira, additional, Goldberg, Aaron D, additional, and Litzow, Mark R., additional

Published
2022
Full Text
View/download PDF

32. Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Author

Badar, Talha, primary, Atallah, Ehab L., additional, Saliba, Antoine N., additional, Shallis, Rory Michael, additional, Stahl, Maximilian F., additional, Bewersdorf, Jan Philipp, additional, Sacchi De Camargo Correia, Guillerhme, additional, Patel, Anand Ashwin, additional, Abaza, Yasmin, additional, Guru Murthy, Guru Subramanian, additional, Duvall, Adam S, additional, Burkart, Madelyn, additional, Palmisiano, Neil, additional, Bradshaw, Danielle, additional, Kota, Vamsi K., additional, Dinner, Shira, additional, Goldberg, Aaron D, additional, and Litzow, Mark R., additional

Published
2022
Full Text
View/download PDF

34. The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias

Author

Xie, Zhuoer, primary, Smith, Alexandra, additional, Komrokji, Rami S., additional, Al Ali, Najla, additional, Patel, Anand Ashwin, additional, Saygin, Caner, additional, Zeidan, Amer M., additional, Bewersdorf, Jan Philipp, additional, Kishtagari, Ashwin, additional, Zeidner, Joshua F., additional, Coombs, Catherine C., additional, Madanat, Yazan F., additional, Foran, James M., additional, Badar, Talha, additional, Desai, Pinkal, additional, Tsai, Charlton, additional, Griffiths, Elizabeth A., additional, Al Malki, Monzr M., additional, Amanam, Idoroenyi, additional, Lai, Catherine, additional, Deeg, Joachim, additional, Ades, Lionel, additional, Arana Yi, Cecilia, additional, Osman, Afaf, additional, Dinner, Shira, additional, Abaza, Yasmin, additional, Chandhok, Namrata, additional, Soong, Deborah, additional, Taylor, Justin, additional, Brunner, Andrew M., additional, Carraway, Hetty E., additional, Singh, Abhay Singh, additional, Geyer, Susan M., additional, Padron, Eric, additional, Patnaik, Mrinal M.M., additional, Savona, Michael R., additional, and Al-Kali, Aref, additional

Published
2022
Full Text
View/download PDF

35. Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

Author

Sallman, David A., primary, DeAngelo, Daniel J., additional, Pemmaraju, Naveen, additional, Dinner, Shira, additional, Gill, Saar, additional, Olin, Rebecca L., additional, Wang, Eunice S., additional, Konopleva, Marina, additional, Stark, Eileen, additional, Korngold, Ana, additional, Haider, Asifa, additional, Backhouse, Kate, additional, Figliola, Carolyn, additional, Lee, Daniel J., additional, Frattini, Mark G., additional, Brownstein, Carrie, additional, and Roboz, Gail J., additional

Published
2022
Full Text
View/download PDF

36. Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.

Author

Mehta-Shah, Neha, primary, Geyer, Susan Michelle, additional, Barta, Stefan K., additional, Amengual, Jennifer Effie, additional, Dockter, Travis, additional, Wright, Chadwick, additional, Dinner, Shira, additional, Hsi, Eric D., additional, Bartlett, Nancy L., additional, Horwitz, Steven M., additional, Kahl, Brad S., additional, Friedberg, Jonathan W., additional, and Leonard, John Paul, additional

Published
2022
Full Text
View/download PDF

37. Racial disparities in patients with TP53 mutated acute myeloid leukemia.

Author

Badar, Talha, primary, Litzow, Mark Robert, additional, Shallis, Rory, additional, Stahl, Maximilian, additional, Bewersdorf, Jan Philipp, additional, Saliba, Antoine N, additional, Sacchi de Camargo Correia, Guilherme, additional, Patel, Anand Ashwin, additional, Abaza, Yasmin, additional, Guru Murthy, Guru Subramanian, additional, Duvall, Adam, additional, Burkart, Madelyn, additional, Al-Kali, Aref, additional, Palmisiano, Neil, additional, Dinner, Shira, additional, Goldberg, Aaron David, additional, and Atallah, Ehab L., additional

Published
2022
Full Text
View/download PDF

38. NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022

Author

Griffiths, Elizabeth A., primary, Roy, Vivek, additional, Alwan, Laura, additional, Bachiashvili, Kimo, additional, Baird, John, additional, Cool, Rita, additional, Dinner, Shira, additional, Geyer, Mark, additional, Glaspy, John, additional, Gojo, Ivana, additional, Hicks, Ashley, additional, Kallam, Avyakta, additional, Kidwai, Wajih Zaheer, additional, Kloth, Dwight D., additional, Kraut, Eric H., additional, Landsburg, Daniel, additional, Lyman, Gary H., additional, Mahajan, Anjlee, additional, Miller, Ryan, additional, Nachar, Victoria, additional, Patel, Seema, additional, Patel, Shiven, additional, Perez, Lia E., additional, Poust, Adam, additional, Riaz, Fauzia, additional, Rosovsky, Rachel, additional, Rugo, Hope S., additional, Simon, Shayna, additional, Vasu, Sumithira, additional, Wadleigh, Martha, additional, Westbrook, Kelly, additional, Westervelt, Peter, additional, Berardi, Ryan A., additional, and Pluchino, Lenora, additional

Published
2022
Full Text
View/download PDF

39. Outcomes ofTP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

Author

Badar, Talha, primary, Atallah, Ehab, additional, Shallis, Rory M., additional, Goldberg, Aaron D., additional, Patel, Anand, additional, Abaza, Yasmin, additional, Bewersdorf, Jan P., additional, Saliba, Antoine N., additional, Correia, Guilherme Sacchi De Camargo, additional, Murthy, Guru, additional, Duvall, Adam, additional, Burkart, Madelyn, additional, Stahl, Maximilian, additional, Liu, Yuanhang, additional, Dinner, Shira, additional, Palmisiano, Neil, additional, Litzow, Mark R., additional, and Foran, James M., additional

Published
2022
Full Text
View/download PDF

41. Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia.

Author

Badar, Talha, Litzow, Mark R., Shallis, Rory M., Patel, Anand, Saliba, Antoine N., Burkart, Madelyn, Bewersdorf, Jan P., Stahl, Maximilian, De Camargo Correia, Guilherme Sacchi, Guru Murthy, Guru Subramanian, Abaza, Yasmin, Duvall, Adam, Bradshaw, Danielle, Kota, Vamsi, Dinner, Shira, Goldberg, Aaron D., Palmisiano, Neil, Al Kali, Aref, and Atallah, Ehab

Subjects
ACUTE myeloid leukemia, STEM cell transplantation, BLACK people, HEMATOPOIETIC stem cell transplantation, HEMATOLOGIC malignancies
Abstract

Background: Although the clinical outcomes of patients with TP53‐mutated acute myeloid leukemia (AML) are dismal, subsets of patients eligible for curative‐intent therapies may fare better. Because racial disparities are known to affect outcome in hematologic malignancies, the authors sought to explore disparities among patients with TP53‐mutated AML. Methods: A multicenter, retrospective study was conducted in a cohort of 340 patients who had TP53‐mutated AML (275 non‐Hispanic White [NHW] and 65 non‐Hispanic Black [NHB]) to analyze differences in treatment and outcome among NHW and NHB patients. Results: The median patient age was comparable between NHW and NHB patients (p =.76). A higher proportion of NHB patients had therapy‐related AML (31% vs. 20%; p =.08) and had co‐mutations (74% vs. 61%; p =.06). A higher proportion of NHW patients received intensive chemotherapy compared with NHB patients (47% vs. 31%; p =.02). Conversely, a higher proportion of NHB patients received low‐intensity chemotherapy (9% vs. 5.5%; p =.02) or best supportive care (22% vs. 7%; p <.001). The complete response rate (including complete responses with or without complete count recovery) was 31% versus 24.5% (p =.39) in NHW and NHB patients, respectively. Only 5% of NHB patients received allogeneic stem cell transplantation compared with 15.5% of NHW patients (p =.02). The proportion of patients who were event‐free (18.5% vs. 8.5%; p =.49) or who remained alive (24.9% vs. 8.3%; p =.13) at 18 months was numerically higher in NHW versus NHB patients, respectively, but was not statistically significant. Conclusions: The current study highlights disparities between NHW and NHB patients with TP53‐mutated AML. Efforts are warranted to eliminate treatment disparities in minority populations. Non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia (AML) were more likely to have concurrent mutations and therapy‐related AML than non‐Hispanic White patients. Non‐Hispanic Black patients who had TP53‐mutated AML received disease‐directed therapies less often compared with non‐Hispanic White patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022

Author

Greenberg, Peter L., primary, Stone, Richard M., additional, Al-Kali, Aref, additional, Bennett, John M., additional, Borate, Uma, additional, Brunner, Andrew M., additional, Chai-Ho, Wanxing, additional, Curtin, Peter, additional, de Castro, Carlos M., additional, Deeg, H. Joachim, additional, DeZern, Amy E., additional, Dinner, Shira, additional, Foucar, Charles, additional, Gaensler, Karin, additional, Garcia-Manero, Guillermo, additional, Griffiths, Elizabeth A., additional, Head, David, additional, Jonas, Brian A., additional, Keel, Sioban, additional, Madanat, Yazan, additional, Maness, Lori J., additional, Mangan, James, additional, McCurdy, Shannon, additional, McMahon, Christine, additional, Patel, Bhumika, additional, Reddy, Vishnu V., additional, Sallman, David A., additional, Shallis, Rory, additional, Shami, Paul J., additional, Thota, Swapna, additional, Varshavsky-Yanovsky, Asya Nina, additional, Westervelt, Peter, additional, Hollinger, Elizabeth, additional, Shead, Dorothy A., additional, and Hochstetler, Cindy, additional

Published
2022
Full Text
View/download PDF

43. Gilteritinib clinical activity in relapsed/refractoryFLT3mutated acute myeloid leukemia previously treated withFLT3inhibitors

Author

Numan, Yazan, primary, Abdel Rahman, Zaid, additional, Grenet, Justin, additional, Boisclair, Stephanie, additional, Bewersdorf, Jan Philipp, additional, Collins, Cailin, additional, Barth, Dylan, additional, Fraga, Martina, additional, Bixby, Dale L., additional, Zeidan, Amer M., additional, Yilmaz, Musa, additional, Desai, Pankil, additional, Mannis, Gabriel, additional, Deutsch, Yehuda E., additional, Abaza, Yasmin, additional, Dinner, Shira, additional, Frankfurt, Olga, additional, Litzow, Mark, additional, Al‐Kali, Aref, additional, Foran, James M., additional, Sproat, Lisa Z., additional, Jovanovic, Borko, additional, Daver, Naval, additional, Perl, Alexander E., additional, and Altman, Jessica K., additional

Published
2022
Full Text
View/download PDF

45. Outcomes and Predictors of Relapse with Use of Hypomethylating Agents in Combination with Venetoclax Prior to Allogeneic Transplant in Acute Myeloid Leukemia

Author

Nizamuddin, Imran, primary, Seijung Oh, Timothy, additional, Numan, Yazan, additional, Kelsten, Max Farber, additional, Burkart, Madelyn, additional, Frankfurt, Olga, additional, Vigil, Carlos E., additional, Abaza, Yasmin, additional, Altman, Jessica K., additional, and Dinner, Shira, additional

Published
2021
Full Text
View/download PDF

46. Myeloid Sarcoma Reveals a Unique Tumor Micro-Environment and Differential Prognosis Based on Transplant Status and Type of Treatment Received

Author

Numan, Yazan, primary, Tariq, Hamza, additional, Fan, Jie, additional, Xie, Ping, additional, Burkart, Madelyn, additional, Abaza, Yasmin, additional, Chen, Yi-Hua, additional, Dinner, Shira, additional, Frankfurt, Olga, additional, Mehta, Jayesh, additional, Zhang, Hui, additional, Altman, Jessica K., additional, and Zhang, Bin, additional

Published
2021
Full Text
View/download PDF

47. Structural and Social Barriers to Survival in Adolescent and Young Adult (AYA) Patients with Acute Myeloid Leukemia (AML)

Author

Burkart, Madelyn, primary, Abraham, Ivy, additional, Rauscher, Garth, additional, Raptis, Nepheli, additional, Zia, Maryam, additional, Patel, Anand Ashwin, additional, Dave, Ami, additional, Berg, Stephanie, additional, Stock, Wendy, additional, Larson, Melissa L., additional, Pearse, William B, additional, Altman, Jessica K., additional, Khan, Irum, additional, and Dinner, Shira, additional

Published
2021
Full Text
View/download PDF

48. Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia

Author

Grenet, Justin, primary, Jain, Akriti G, additional, Burkart, Madelyn, additional, Waksal, Julian, additional, Famulare, Christopher, additional, Numan, Yazan, additional, Stahl, Maximilian, additional, Mckinnell, Zoe, additional, Ball, Brian, additional, Ma, Xiaoyue, additional, Christos, Paul J, additional, Ritchie, Ellen, additional, Samuel, Michael B., additional, Kaner, Justin D., additional, Lee, Sangmin, additional, Goldberg, Aaron D, additional, Dinner, Shira, additional, Sweet, Kendra, additional, Roboz, Gail J., additional, and Desai, Pinkal, additional

Published
2021
Full Text
View/download PDF

49. A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)

Author

O'Donnell, Elizabeth K., primary, Suman, Vera Jean, additional, Geyer, Susan M., additional, Nadeem, Omar, additional, Dinner, Shira, additional, Yee, Andrew J., additional, Laubach, Jacob P., additional, Mo, Clifton C., additional, Tuchman, Sascha A., additional, Donadio, Kristen, additional, Sinclair, Sarah, additional, Raje, Noopur S., additional, and Richardson, Paul G., additional

Published
2021
Full Text
View/download PDF

50. Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152

Author

Palmisiano, Neil, primary, Lee, Ju-Whei, additional, Claxton, David F., additional, Paietta, Elisabeth, additional, Alkhateeb, Hassan B., additional, Park, Jae H, additional, Podoltsev, Nikolai, additional, Atallah, Ehab L., additional, Schaar, Dale G, additional, Dinner, Shira, additional, Webster, Jonathan, additional, Luger, Selina M., additional, and Litzow, Mark R., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results